Skip to main content
Premium Trial:

Request an Annual Quote

From the Shoulders of a Giant

Premium

Looks like Shimadzu wants to join in the proteomics games. The company just spun out Shimadzu Biotech, headquartered in Kyoto, Japan, and led by its former head of life sciences, Tetsuo Ichikawa. The spinoff is “not a single corporation but a strategic global unit,” Ichikawa says; it will draw on the parent company’s subsidiaries in the US, Europe, and Australia. Shimadzu Biotech inherits a $43 million business in bioscience and expects that to grow to more than $170 million within three years.

According to Ichikawa, Shimadzu Biotech will focus on proteomics and DNA analysis. He predicts most of its sales will be from instruments and the remaining quarter from services and reagents, though the goal is to get services and reagents to comprise three-fourths of the company’s sales. Already, Shimadzu’s mass spec technology (the TOFMAS/AXIMA) has been the basis for partnerships with Sigma-Aldrich, Proteome Systems, and LumiCyte. Not bad for a newbie.

— Meredith Salisbury

 

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.